Table 5 Predicted serotype-specific vaccine effectiveness for the PCV7 serotypes in PCV13: Estimations using serotype-specific protective threshold compared to the estimations using pan-serotype 0.35 µg/mL correlate of protection.
Serotype | Vaccine effectiveness (95% CI) based on estimated serotype-specific threshold | Vaccine effectiveness based on 0.35 µg/mL correlate of protection | ||||
|---|---|---|---|---|---|---|
United Kingdom | Australia | Germany | United Kingdom | Australia | Germany | |
4 | 97% (61–100) | 87% (59–97) | 35% (2–97) | 98% | 99% | 99% |
6B | 86% (3–100) | 70% (15–94) | 94% (61–100) | 44% | 95% | 78% |
9 V | 75% (1–98) | 60% (26–82) | 80% (1–99) | 86% | 95% | 98% |
14 | 97% (86–100) | 86% (26–99) | 97% (68–100) | 99% | 100% | 99% |
18 C | 99% (86–100) | 80% (11–98) | 74% (3–97) | 90% | 98% | 98% |
19 F | 91% (50–99) | 12% (2–89) | 56% (4–91) | 100% | 100% | 96% |
23 F | 87% (22–99) | 67% (3–93) | 88% (6–99) | 72% | 84% | 87% |
Aggregate | 93% (20–100) | 71% (3–97) | 91% (5–100) | 97% | 98% | 95% |
Reported aggregate VEa | 90% (34–98)b | 70% (−8–92)c | 90% (57–98)d | 90% (34–98)b | 70% (−8–92)c | 90% (57–98)d |
